Maisong Cai - Sinopharm Group VP
| X2S Stock | EUR 2.64 0.04 1.54% |
Insider
Maisong Cai is VP of Sinopharm Group Co
| Age | 53 |
| Phone | 86 21 2305 2666 |
| Web | https://www.sinopharmgroup.com.cn |
Sinopharm Group Management Efficiency
The company has return on total asset (ROA) of 0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. Sinopharm Group's management efficiency ratios could be used to measure how well Sinopharm Group manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Steven Paladino | Henry Schein | 66 | |
| Patricia English | Cardinal Health | 43 | |
| Andrea Frohning | Patterson Companies | 53 | |
| Michelle Greene | Cardinal Health | N/A | |
| Min Zuo | Shanghai Pharmaceuticals Holdin | 57 | |
| Dawei Liu | Shanghai Pharmaceuticals Holdin | 38 | |
| Kathy Gaddes | AmerisourceBergen | 60 | |
| Craig Cowman | Cardinal Health | N/A | |
| Wenxun Huo | Shanghai Pharmaceuticals Holdin | 62 | |
| Michael Ettinger | Henry Schein | 62 | |
| Jinqi Yu | Shanghai Pharmaceuticals Holdin | N/A | |
| Haoliang Gu | Shanghai Pharmaceuticals Holdin | 57 | |
| Donald Zurbay | Patterson Companies | 55 | |
| Shivani Kaul | Patterson Companies | N/A | |
| Olga Timoshkina | Henry Schein | N/A | |
| Stephen Mason | Cardinal Health | 51 | |
| Ronald Lombardi | Prestige Consumer Healthcare | 59 | |
| Jianyi Mao | Shanghai Pharmaceuticals Holdin | 50 | |
| Jeffrey Zerillo | Prestige Consumer Healthcare | 62 | |
| Shunjiang Yu | Shanghai Pharmaceuticals Holdin | N/A | |
| Ronald South | Henry Schein | 61 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 |
Sinopharm Group Leadership Team
Elected by the shareholders, the Sinopharm Group's board of directors comprises two types of representatives: Sinopharm Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinopharm. The board's role is to monitor Sinopharm Group's management team and ensure that shareholders' interests are well served. Sinopharm Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinopharm Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yijian Wu, Company Board | ||
| Xiaojuan Li, Chief Officer | ||
| Qingming Yu, Ex Chairman | ||
| Yong Liu, Pres Director | ||
| Shuangjun Xu, NonEx VP | ||
| Xiuchang Jiang, CFO VP | ||
| Wanyong Lian, VP | ||
| Maisong Cai, VP |
Sinopharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sinopharm Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 15.96 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 50.99 % | |||
| Price To Earning | 6.10 X | |||
| Price To Book | 0.89 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Sinopharm Stock
Sinopharm Group financial ratios help investors to determine whether Sinopharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.